SATIVUS TECH CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SATIVUS TECH CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $36.3K | Jan 10, 2018 |
| FY2017 | Sep 30, 2016 | $137.5K | Jan 10, 2018 |
| FY2016 | Sep 30, 2015 | $110.2K | Jan 13, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $12.5K | Jan 10, 2018 |
| FY2017 | Sep 30, 2016 | $48.0K | Jan 10, 2018 |
| FY2016 | Sep 30, 2015 | $53.0K | Jan 13, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($869.0K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($680.0K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($324.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.53M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.94M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $7.64M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($16.58M) | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | ($1.71M) | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | ($5.15M) | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | ($1.10M) | Jan 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.06M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($958.0K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($815.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($1.33M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.55M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($563.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($273.0K) | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | ($27.0K) | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | ($4.95M) | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | ($1.05M) | Jan 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $694.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $687.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $253.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $673.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $911.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $107.0K | Mar 31, 2022 |
| FY2018 | Sep 30, 2018 | $2.01M | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | $532.0K | Jan 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($701.0K) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($488.0K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($932.0K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($986.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.37M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($316.0K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.04M) | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | ($1.87M) | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | ($1.96M) | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | $27.0K | Jan 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $269.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $79.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $206.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.0K | Mar 31, 2023 |
| FY2020 | Dec 31, 2018 | $100.0K | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | $906.0K | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | $15.0K | Jan 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $558.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.41M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.15M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.02M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $418.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.0K | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | $12.0K | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | $3.13M | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | $1.36M | Jan 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.84M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $3.23M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $3.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.72M | Apr 1, 2024 |
| FY2017 | Sep 30, 2017 | $52.4K | Jan 10, 2018 |
| FY2017 | Sep 30, 2016 | $15.4K | Jan 10, 2018 |
| FY2016 | Sep 30, 2015 | $4.6K | Jan 13, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.50M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($2.92M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($2.28M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($2.84M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($2.48M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($2.05M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($10.66M) | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | ($3.11M) | Mar 17, 2021 |
| FY2020 | Sep 30, 2018 | ($3.39M) | Mar 17, 2021 |
| FY2018 | Sep 30, 2017 | ($368.0K) | Jan 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.48M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($23.61M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($22.93M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($22.60M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($21.08M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($17.46M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($25.10M) | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | ($8.52M) | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | ($6.81M) | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | ($1.67M) | Jan 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $96.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $176.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $810.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $866.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $411.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.0K | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | $10.0K | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | $472.0K | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | $744.0K | Jan 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.22M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 4.22M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 4.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.22M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 4.20M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 3.17M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 20.54M | Mar 17, 2021 |
| FY2020 | Dec 31, 2018 | 16.20M | Mar 17, 2021 |
| FY2018 | Sep 30, 2018 | 15.00M | Jan 15, 2019 |
| FY2018 | Sep 30, 2017 | 10.36M | Jan 15, 2019 |